Back Back
Cell No. : Cell Name
RCB0882 : OCUB-F  update : 2022/03/24
CommentSame as OCUB-1, OCUB-M.
Comment from the depositorChromosome = pseudodiploid
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Sawada, Tetsuji
Originator Sawada, Tetsuji
Year of deposit 1993
Original cell OCUB-1
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 53 years
Tissue mammary gland, pleural fluid
Disease name mammary tumor
Metastastatic ability Yes
Metastatsd tissue chest wall, pleura
Classification cancer
Year of origin 1988
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_3352
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Medium and additives DMEM (low glucose) + 10% FBS + 0.5mM Sodium Pyruvate
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 10 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) (-)
Isozyme LD, NP
Chromosome mode 70-161(50) : /75(6),76(2),77(3),78(2),79(5),80(12)/
STR(human) OK
deposit info
lot info
Reference information Reference 2
User's Publication 11

To topTop
5477  Ikeda K, Yashiro M, Sawada T, Hato F, Hasuma T, Ishikawa T, Hirakawa-YSChung K.  M(R) 77 KDA factor derived from fibroblasts stimulates the invasion ability of breast-cancer cells.  Int J Cancer  2001  92(2):181-6  PubMed ID: 11291043
1881  Sawada T, Chung, Y S, Nakata B, Kubo T, Kondo Y, Sogabe T, Onoda N, Ogawa Y, Yamada N, Sowa M  [Establishment and characterization of a human breast cancer cell line, OCUB-1]  Hum Cell  1994  7:138-44  PubMed ID: 7873497

To topTop
User's Publication
11747  Halilovic A, Verweij DI, Simons A, Stevens-Kroef MJPL, Vermeulen S, Elsink J, Tops BBJ, Otte-Höller I, van der Laak JAWM, van de Water C, Boelens OBA, Schlooz-Vries MS, Dijkstra JR, Nagtegaal ID, Tol J, van Cleef PHJ, Span PN, Bult P.  HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.  Sci Rep  2019    PubMed ID: 31406196
12199  Masashi Namba, Noboru Hattori, Hironobu Hamada, Kakuhiro Yamaguchi, Yohei Okamoto, Taku Nakashima, Takeshi Masuda, Shinjiro Sakamoto, Yasushi Horimasu, Shintaro Miyamoto, Hiroshi Iwamoto, Kazunori Fujitaka, Nobuoki Kohno  Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1  Cancer Lett  2019  442:31-39  PubMed ID: 30389434
8492  Hollestelle A, Elstrodt F, Timmermans M, Sieuwerts AM, Klijn JG, Foekens JA, den Bakker MA, Schutte M.  Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations.  Breast Cancer Res. Treat.  2010  122:125-33 
8470  Ng SS, Mahmoudi T, Danenberg E, Bejaoui I, de Lau W, Korswagen HC, Schutte M, Clevers H.  Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade.  J. Biol. Chem.  2009  284:35308-13  PubMed ID: 19850932
8695  Hambach L, Ling KW, Pool J, Aghai Z, Blokland E, Tanke HJ, Bruijn JA, Halfwerk H, van Boven H, Wieles B, Goulmy E.  Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.  Blood  2009  113:2715-22  PubMed ID: 19096014
5012  Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K.  Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.  Hum Mol Genet  2006  15(6):821-30  PubMed ID: 16439445
14326  van Wezel T, Lombaerts M, van Roon EH, Philippo K, Baelde HJ, Szuhai K, Cornelisse CJ, Cleton-Jansen AM.  Expression analysis of candidate breast tumour suppressor genes on chromosome 16q  Breast Cancer Res  2005  7(6):R998-1004  PubMed ID: 16280054
3796  Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.  Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.  Int J Cancer  2003  107(1):53-9  PubMed ID: 12925956
14333  Su GH, Song JJ, Repasky EA, Schutte M, Kern SE.  Mutation rate of MAP2K4/MKK4 in breast carcinoma  Hum Mutat  2002  19(1):81  PubMed ID: 11754110
16914  van de Wetering M, Barker N, Harkes IC, van der Heyden M, Dijk NJ, Hollestelle A, Klijn JG, Clevers H, Schutte M.  Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling  Cancer Res  2001  ;61(1):278-84.  PubMed ID: 11196175
13694  Kawamoto M, Shichijo S, Imai Y, Imaizumi T, Koga T, Yanaga H, Itoh K.  Expression of the SART-1 tumor rejection antigen in breast cancer  Int J Cancer  1999  80(1):64-7  PubMed ID: 9935232

Back Back Return Top Page